Juvion Life Sciences Sàrl

Juvion is pioneering a first-in-class approach to aging therapeutics by preserving neuron-muscle communication, a critical factor in mobility and longevity. As an EPFL spin-off, Juvion integrates AI-driven drug discovery, neuroscience, and robotics into a proprietary in vivo screening platform to develop next-generation therapeutics aimed at tackling immobility and delaying diseases such as sarcopenia and motor neuropathy. One of our lead compounds, JUV-001, a natural plant-derived solution, has demonstrated a significant impact on preserving mobility in old age in preclinical models. With patent protection, strong industry partnerships, and a scalable business model, Juvion is set to redefine aging healthcare by delivering accessible, first-in-class solutions that extend heathspan.